Medicine and Dentistry
Biological Marker
100%
Kidney Metastasis
100%
Overall Survival
100%
Nivolumab
80%
Progression Free Survival
60%
Sunitinib
40%
Targeted Therapy
40%
Neutrophil
40%
Vasculotropin
40%
Ipilimumab
40%
Immune Checkpoint Inhibitor
40%
Leukocyte
20%
Solid Malignant Neoplasm
20%
Group Therapy
20%
Non Small Cell Lung Cancer
20%
Univariate Analysis
20%
Systemic Therapy
20%
Multivariate Analysis
20%
Prospective Study
20%
Sodium Fluoride
20%
Antiangiogenic Therapy
20%
Lactate Dehydrogenase
20%
Factor XII
20%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Overall Survival
100%
Kidney Metastasis
100%
Nivolumab
80%
Progression Free Survival
60%
Sunitinib
40%
Vasculotropin
40%
Ipilimumab
40%
Immune Checkpoint Inhibitor
40%
Solid Malignant Neoplasm
20%
Prospective Study
20%
Non Small Cell Lung Cancer
20%
Sodium Fluoride
20%
Lactate Dehydrogenase
20%
Systemic Treatment
20%
Antiangiogenic Therapy
20%
Blood Clotting Factor 12
20%
Keyphrases
Lung Immune Prognostic Index
100%